MAASTRICHT, the Netherlands — The landscape of acute ischemic stroke management is undergoing a significant transformation. For years, the gold standard for mechanical thrombectomy—a procedure where a catheter is used to physically remove a blood clot—was strictly confined to a narrow therapeutic window of six hours. While subsequent clinical trials like DAWN and DEFUSE 3 extended this window to 24 hours for specific patients, many clinicians remained hesitant to push beyond these boundaries.
Recent findings presented at the European Stroke Organisation Conference 2026 have shattered these conservative paradigms. Two landmark randomized controlled trials, LATE-MT and MILD-MT, demonstrate that mechanical thrombectomy significantly improves functional outcomes for patients previously considered outside the scope of intervention: those presenting beyond 24 hours and those exhibiting only mild symptoms.
The Evolution of Stroke Care: A Chronological Perspective
To understand the weight of these findings, one must look at the progression of endovascular therapy. Initially, thrombectomy was restricted to a "golden window" of six hours, based on the assumption that irreversible brain damage occurred rapidly following large-vessel occlusion (LVO).
As imaging technology advanced, particularly the rise of perfusion-weighted CT and MRI, clinicians began identifying "slow progressors"—patients whose brain tissue remained salvageable long after the initial stroke onset due to collateral blood flow. This realization led to the extension of the treatment window to 24 hours. However, the period between 24 and 72 hours remained a "no-man’s land" in clinical practice, characterized by caution and a lack of randomized evidence.
Simultaneously, the treatment of mild strokes (defined by an NIHSS score below 6) has been a point of contention. While guidelines were historically non-committal due to a lack of robust data, many large-volume stroke centers began adopting more aggressive approaches, treating mild cases to prevent the sudden, catastrophic deterioration often seen in LVO patients. The 2026 conference provided the definitive, high-level evidence required to formalize these shifts.
LATE-MT: Extending the Window to 72 Hours
The LATE-MT trial, presented by Jianmin Liu, MD, of Changhai Hospital, Shanghai, addressed the critical question of whether reperfusion therapy holds value for patients presenting 24 to 72 hours post-stroke.
Study Design and Patient Population
The trial enrolled 336 patients across multiple sites, all presenting with anterior circulation LVOs. The criteria for inclusion were rigorous: patients required an NIHSS score of 6 or higher and, crucially, a favorable CT perfusion mismatch profile. This profile—defined as an infarct core volume under 50 mL and a mismatch ratio of 1.8 or greater—served as the biological indicator that brain tissue remained viable despite the late presentation. The median time from stroke onset to randomization was 38.5 hours.
Clinical Outcomes
The primary endpoint was the shift in the modified Rankin Scale (mRS) score at 90 days, a standard metric for assessing disability. The results were compelling: the thrombectomy arm demonstrated a significantly improved functional outcome compared to standard medical care alone (adjusted common OR 0.47).
Patients treated with thrombectomy showed a marked reduction in long-term disability, with fewer patients falling into the higher mRS categories of 3-6 or 3-5. Furthermore, improvements were observed in quality-of-life metrics and the Barthel Index, which measures a patient’s independence in daily living activities. While infarct volume at seven days did not differ significantly between the groups, the recanalization rate—the ability to successfully clear the clot—was 82.4% in the intervention arm versus 18.0% in the control group.
Safety Concerns and the "Trade-off"
Despite the efficacy, the trial highlighted safety risks. The thrombectomy arm experienced higher rates of death (6.0% vs 1.8%), any intracerebral hemorrhage (28.3% vs 5.5%), and symptomatic hemorrhage (4.8% vs 0).
Co-author Craig Anderson, MD, of the George Institute for Global Health, characterized these findings as a delicate balance. "It’s a trade-off, isn’t it? That you can save the disability, but there is a small complication," Dr. Anderson remarked. He noted that the mortality signal likely reflects the frailty of the patient population and the inherent risks of reperfusion in a very late time window, rather than a failure of the procedure itself.
MILD-MT: Challenging the "Wait-and-See" Approach
While LATE-MT looked at time, MILD-MT addressed symptom severity. Historically, patients with an NIHSS score below 6 were often monitored rather than treated, under the assumption that their symptoms were too minor to warrant the risks of surgery.
The Risk of Deterioration
The MILD-MT trial, conducted at 26 Chinese centers, challenged this "watchful waiting" strategy. The study randomized 300 patients who presented within 24 hours of stroke onset with mild symptoms. Investigators utilized perfusion imaging to identify patients at high risk of early neurological deterioration (END).
Superiority of Intervention
The findings were stark. The primary efficacy endpoint—an excellent functional outcome (mRS 0-1) at 90 days—was achieved by 69.4% of patients in the thrombectomy group compared to only 50.0% in the control group.
Furthermore, while there was no significant difference in early neurological deterioration at 24 hours, by the seven-day mark, the thrombectomy group showed a significantly lower rate of deterioration (13.9% vs 31.4%). The intervention proved that even in mild cases, proactive removal of the occlusion prevents the "ticking time bomb" effect often seen in LVO strokes.
Expert Perspectives and Implications for Clinical Practice
The medical community has reacted with cautious optimism. Ettore Nicolini, MD, PhD, from Sapienza University of Rome, emphasized that LATE-MT provides the first randomized evidence for ultra-late thrombectomy. "We had some evidence from observational studies, but it is the first randomized evidence," he stated. However, he stressed that the positive outcomes are contingent upon the rigorous use of perfusion imaging to select the right candidates.
Jelle Demeestere, MD, PhD, of University Hospitals Leuven, echoed these sentiments regarding the MILD-MT trial. "The main message of the study is probably that if we see patients with mild stroke, don’t wait and see because they have a high chance of deteriorating," he noted.
The Path Forward
The implications for clinical practice are profound:
- Standardization of Imaging: Both trials underscore that high-quality perfusion imaging is no longer optional; it is the cornerstone of safe, extended-window, and mild-stroke interventions.
- Shift in Guidelines: The consistency of these results with recent trends in large stroke centers suggests that future international guidelines will likely incorporate these findings, formalizing the use of thrombectomy for patients previously deemed ineligible.
- Global Verification: Experts agree that while the results are promising, replicating these findings in diverse patient populations outside of China is a necessary next step to confirm the global generalizability of these outcomes.
Ultimately, the results from Maastricht signify that the era of "time-is-brain" is evolving into "tissue-is-brain." By focusing on the biological viability of the tissue rather than arbitrary time limits or initial symptom severity, the medical community is moving toward a more personalized, effective, and aggressive approach to stroke care. While complications remain a reality, the ability to prevent long-term disability for a wider cohort of patients represents a major victory for interventional neurology.
